NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
Status:
Active, not recruiting
Trial end date:
2027-02-16
Target enrollment:
Participant gender:
Summary
The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside
(NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Akershus
Collaborators:
Haukeland University Hospital Oslo University Hospital South-Eastern Norway Regional Health Authority St. Olavs Hospital Sykehuset Innlandet HF The Bergesen Foundation University Hospital of North Norway University of Bergen